![\"NED](\"https:\/\/www.send2press.com\/wire\/images\/20-0902-ned-biosystems-696x522.jpg\")
<\/em><\/p>\nDr. El-Bardeesy is Associate Professor of Medicine at the Harvard Medical School and a leading authority on the causes of cancer. Dr. El-Bardeesy also serves as the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board Co-Chair. Dr. El-Bardeesy additionally is Assistant Professor at Massachusetts General Hospital Cancer Center and is an instructor at the Dana-Farber Cancer Institute. Dr. El-Bardeesy is widely published on the molecular and cellular mechanisms that drive certain types of cancer.<\/p>\n
Dr. Kurzrock is Professor of Medicine and Associate Director for Clinical Sciences at the University of San Diego Moore Cancer Center. She leads the Center\u2019s clinical trial programs and heads its recently established Center for Personalized Cancer Therapy. Dr. Kurzrock\u2019s distinguished track record includes leading one of the largest phase one clinical trial programs at the University of Texas MD Anderson Cancer Center, where she spearheaded an innovative approach that utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized the possibility for response.<\/p>\n
\u201cThe addition of Dr. El-Bardeesy and Dr. Kurzrock to the Scientific Advisory Board further strengthens the resolve of NED\u2019s mission to innovate safe, effective and transformative treatments for cancer and other life-threatening diseases such as Covid-19,\u201d stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems\u2019 Board. \u201cAs we advance NED-170 clinical trials for cholangiocarcinoma, ovarian and triple negative breast cancer to establish the product\u2019s safety and efficacy, we will rely heavily on the Scientific Advisory Board\u2019s expert guidance and direction. They will also play an instrumental role in our efforts to launch clinical trials for NED-260, a potential treatment and prophylaxis for COVID-19.*\u201d<\/p>\n
NED-170 is a patented investigational cancer therapy that the Company believes is the first to address and affect four key processes that advance all late-stage cancers (Stages II-IV). The same four processes that drive advanced cancers are integral to the pathology of Covid-19.<\/p>\n
\u201cThe implementation of comprehensive clinical trials is a vitally important step in determining the safety and effectiveness of the treatments for life threatening illnesses that we are innovating at NED Biosystems,\u201d stated Geoffrey Ling, COL(ret) MD, PhD, Office of the CEO, and member of the Scientific Advisory Board and Board of Directors, NED Biosystems and member of the U.S. Government\u2019s Covid-19 Task Force. \u201cThe deep expertise of our Scientific Advisory Board provides us with the confidence that we are following the proper methods and techniques to generate a valid set of trial results.\u201d<\/p>\n
\u201cDr. Kurzrock and Dr. El-Bardeesy will provide invaluable guidance on the clinical design and execution for our upcoming NED-170 trials, as well as input into the analysis of the results,\u201d stated Brian Leyland-Jones, BS, MBBS, PhD, FRACP, FRACPC, NED Biosystems Chair of the Scientific Advisory Board. \u201cWe are excited to welcome them to the Scientific Advisory Board and look forward to their support of our clinical trial initiatives.\u201d<\/p>\n
About NED Biosystems™<\/strong><\/p>\n Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments unlike most available today. Beginning with a focus on patients and their families, NED seeks to dramatically improve patients\u2019 outcomes with therapies that lack the toxicity and side effects of today\u2019s treatments, allowing patients to retain a high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations but also in economically challenged global regions.<\/p>\n
![https:\/\/www.Send2Press.com\/300dpi\/20-0902s2p-nedbio-300dpi.jpg<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"CAMBRIDGE, Mass., Sept. 2, 2020 (SEND2PRESS NEWSWIRE) — NED Biosystems, an innovative clinical-stage biotech company developing oral therapies for cancer and novel coronavirus, is pleased to announce that Nabeel El-Bardeesy, PhD and Razelle Kurzrock, MD have joined the Company’s Scientific Advisory Board.<\/p>\n","protected":false},"author":8465,"featured_media":62970,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[499,12804,1,61,317,161],"tags":[28,14156],"class_list":["post-63101","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-research-news","category-ap","category-business-news","category-health-medical-news","category-career-news","category-massachusetts-news","tag-cancer-research","tag-clinical-stage-biotech-company","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":4719,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/63101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/8465"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=63101"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/63101\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media\/62970"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=63101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=63101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=63101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}](\"https:\/\/www.Send2Press.com\/300dpi\/20-0902s2p-nedbio-300dpi.jpg\"){kind=link}